NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer
February 4, 2026
Boston, MA, – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic